Related Experiment Videos
Uric acid promotes tumor immune rejection
De-En Hu1, Alistair M Moore, Lindy L Thomsen
1Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, United Kingdom.
Cancer Research
|August 4, 2004
Summary
Uric acid, a danger signal, enhances immune responses against tumors by maturing dendritic cells. Inhibiting or removing uric acid delayed tumor rejection, while administering it enhanced the process.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Uric acid from dying cells signals the immune system, promoting dendritic cell maturation and T-cell responses.
- This uric acid-mediated immune stimulation is a proposed mechanism for anti-tumor immunity.
- Elevated uric acid levels are observed in tumors undergoing immune rejection.
Purpose of the Study:
- To investigate the role of uric acid in tumor immune rejection.
- To determine the effects of modulating uric acid levels on anti-tumor immune responses.
Main Methods:
- Measuring uric acid levels in tumors undergoing immune rejection.
- Inhibiting uric acid production using allopurinol.
- Removing uric acid using uricase.
- Administering crystalline uric acid subcutaneously.
Main Results:
- Uric acid levels were elevated in tumors experiencing immune rejection.
- Inhibition of uric acid production (allopurinol) or its removal (uricase) delayed tumor immune rejection.
- Subcutaneous administration of crystalline uric acid enhanced tumor immune rejection.
Conclusions:
- Uric acid plays a crucial role in promoting tumor immune rejection.
- Modulating uric acid levels can significantly impact the efficacy of anti-tumor immune responses.